Your web browser doesn’t have the Flash Player v.9 plugin installed, so this Website can’t be properly viewed.
For full experience, please download the latest Flash plugin at Adobe.com.
Download Adobe Flash Player now.
Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine
GARDASIL® is a vaccine that helps protect against 4 types of human papillomavirus (HPV): 2 types that cause 70% of cervical cancers in women, and 2 more types that cause 90% of genital warts in men and women.
GARDASIL® has also been shown to help protect against vulvar and vaginal cancers, as well as abnormal and pre-cancerous cervical cells (as found in abnormal Pap tests) in women.
GARDASIL® is for girls and women ages 9 to 26, and boys and men ages 9 to 26. Vaccination is recommended for girls and boys as young as 9 because GARDASIL® works best when given before there is any contact with HPV types 6, 11, 16, and 18.
If you’re already sexually active, you can still benefit from GARDASIL®. If you are already infected with one type of HPV contained in the vaccine, GARDASIL® will help protect you against the other three types. That means GARDASIL® could still help protect you against HPV types you haven’t been exposed to.
As with all vaccines, GARDASIL® may not fully protect everyone who gets the vaccine. GARDASIL® will not protect against all types of HPV, and it will not protect against other diseases that are not caused by HPV. Your healthcare professional can help you understand more.
If you are considering GARDASIL® for your son or your daughter, learn more here.
GARDASIL® is given in 3 doses over 6 months. Take a closer look at the vaccination schedule:
If you’ve already gotten your first dose of GARDASIL® and want to be reminded about your next 2, we can help.
GARDASIL® is a vaccine indicated in girls and women 9-26 years of age, for the prevention of infection caused by HPV types 6, 11, 16 and 18, and the following diseases associated with these types: cervical cancer, abnormal and precancerous cervical cells, vulvar and vaginal cancers, abnormal and precancerous vulvar and vaginal cells, and genital warts. GARDASIL® is indicated in boys and men 9-26 years of age for the prevention of infection caused by HPV types 6, 11, 16 and 18, and genital warts caused by HPV types 6 and 11.
GARDASIL® helps prevent these diseases but it does not treat them. And just like all vaccines, GARDASIL® may not fully protect everyone who gets it. GARDASIL® does not protect against all types of HPV. Duration of protection over the long term has not been established. Vaccination with GARDASIL® is not recommended during pregnancy. GARDASIL® may cause side effects and allergic reactions.
Even if you get vaccinated with GARDASIL®, it is still important for women to continue having regular Pap tests.
Only a healthcare professional can decide if GARDASIL® is right for you, your son or your daughter.
Read the Patient Product Information or the Prescribing Information for more information.
This site is intended only for residents of Canada. This Website is for information purposes only.
®Registered Trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Used under license.
©2010 MERCK FROSST CANADA LTD. All rights reserved.
08-11-HPV-10-CDN-84140662-AV